Activin Receptors, Type II
"Activin Receptors, Type II" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
One of the two types of ACTIVIN RECEPTORS. They are membrane protein kinases belonging to the family of PROTEIN-SERINE-THREONINE KINASES. The major type II activin receptors are ActR-IIA and ActR-IIB.
MeSH Number(s)
D08.811.913.696.620.682.700.062.750
D12.776.543.750.750.400.820.500.750
Below are MeSH descriptors whose meaning is more general than "Activin Receptors, Type II".
Below are MeSH descriptors whose meaning is more specific than "Activin Receptors, Type II".
This graph shows the total number of publications written about "Activin Receptors, Type II" by people in Harvard Catalyst Profiles by year, and whether "Activin Receptors, Type II" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1999 | 0 | 1 | 1 |
2000 | 0 | 1 | 1 |
2001 | 1 | 0 | 1 |
2002 | 1 | 1 | 2 |
2003 | 0 | 1 | 1 |
2004 | 0 | 1 | 1 |
2005 | 1 | 3 | 4 |
2006 | 2 | 1 | 3 |
2007 | 1 | 0 | 1 |
2008 | 2 | 1 | 3 |
2009 | 4 | 4 | 8 |
2010 | 0 | 2 | 2 |
2011 | 4 | 1 | 5 |
2012 | 2 | 4 | 6 |
2013 | 3 | 2 | 5 |
2014 | 4 | 3 | 7 |
2015 | 1 | 1 | 2 |
2016 | 4 | 1 | 5 |
2017 | 4 | 1 | 5 |
2018 | 2 | 3 | 5 |
2019 | 2 | 0 | 2 |
2020 | 1 | 2 | 3 |
2021 | 2 | 3 | 5 |
2023 | 0 | 4 | 4 |
Below are the most recent publications written about "Activin Receptors, Type II" by people in Profiles.
-
Mutation of key signaling regulators of cerebrovascular development in vein of Galen malformations. Nat Commun. 2023 11 17; 14(1):7452.
-
Executive summary of the 14th HHT international scientific conference. Angiogenesis. 2023 08; 26(Suppl 1):27-37.
-
Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes. Blood Adv. 2023 07 25; 7(14):3677-3679.
-
Defining the clinical validity of genes reported to cause pulmonary arterial hypertension. Genet Med. 2023 11; 25(11):100925.
-
Identification and validation of a novel pathogenic variant in GDF2 (BMP9) responsible for hereditary hemorrhagic telangiectasia and pulmonary arteriovenous malformations. Am J Med Genet A. 2022 03; 188(3):959-964.
-
ß-Thalassemia: evolving treatment options beyond transfusion and iron chelation. Hematology Am Soc Hematol Educ Program. 2021 12 10; 2021(1):600-606.
-
Prevalence of and Factors Associated with Arterial Aneurysms in Patients with Hereditary Hemorrhagic Telangiectasia: 17-Year Retrospective Series of 418 Patients. J Vasc Interv Radiol. 2021 12; 32(12):1661-1669.
-
Clinical and molecular characterization of patients with hereditary hemorrhagic telangiectasia: Experience from an HHT Center of Excellence. Am J Med Genet A. 2021 07; 185(7):1981-1990.
-
ActRIIB:ALK4-Fc alleviates muscle dysfunction and comorbidities in murine models of neuromuscular disorders. J Clin Invest. 2021 02 15; 131(4).
-
Outcome of lower-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) after failure of erythropoiesis- stimulating agents. Leuk Res. 2020 12; 99:106472.